This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: August 13th, 2010 - August 13th, 2011
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma.
Target Audience
The educational design of this activity addresses the needs of physicians, nurses, and pharmacists involved in the treatment of patients with multiple myeloma.
Learning Objectives
At the completion of this activity participants should be able to:
- Describe optimal frontline treatment options for patients with newly diagnosed multiple myeloma (MM)
- Describe current opinion on maintenance therapy for MM
- List therapeutic options for patients with relapsed/refractory MM
- Summarize key clinical data on the use of novel agents in the treatment of MM as presented at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting
Agenda - 1.25 hours
• Articles/Commentaries: 60 minutes
• Evaluation/Post-Test: 15 minutes
Physician Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.
Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal program number for this activity is 0468-9999-10-048-H01-P.
Disclosure Statement
Global Education Group (Global) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity::
|
Name of Planner or Manager |
Company |
Reported Financial Relationship |
| Amanda Glazar, PhD | Global | Nothing to disclose |
| Jackie Dawson, MSN | Global | Nothing to disclose |
| Kathryn Gada, MSN | MLI | Nothing to disclose |
| Nancy Nesser, PharmD, JD | MLI | Nothing to disclose |
| Karen Cooksey | COEXM | Nothing to disclose |
Faculty Disclosures
Paul Richardson, MD, is on the advisory boards for Celgene, Johnson & Johnson, Millennium, and Novartis and has received research support from Celgene and Millennium.
William Bensinger, MD, is on the speaker's bureau for Celgene, is a consultant to Millennium, and has received research grants from AstraZeneca, Celgene, Genzyme, Geron, Millennium, and Onyx.
Kenneth Anderson, MD is on the advisory board for Celgene, Gentium, Millennium, and Novartis, has received grant/research support from Celgene, Millennium, and Novartis, has received honoraria from Celgene, Millennium, and Novartis, and is on the speaker's bureau for Celgene and Millennium.
Melissa Alsina, MD is on the advisory board for Celgene and Millennium.
*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.
*Content will include non-FDA-approved uses.
Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.
